Equities Analysts Set Expectations for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Exelixis in a research note issued on Monday, April 28th. William Blair analyst A. Hsieh forecasts that the biotechnology company will post earnings per share of $0.44 for the quarter. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. William Blair also issued estimates for Exelixis' Q2 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.50 EPS and Q4 2026 earnings at $0.52 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Several other research firms also recently weighed in on EXEL. UBS Group restated an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Oppenheimer downgraded Exelixis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 19th. Stephens restated an "equal weight" rating and issued a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Trading Down 6.7 %

NASDAQ:EXEL traded down $2.69 during trading hours on Thursday, reaching $37.16. 2,041,830 shares of the company were exchanged, compared to its average volume of 2,155,923. The stock's 50-day moving average is $37.00 and its 200-day moving average is $35.20. Exelixis has a twelve month low of $20.14 and a twelve month high of $40.26. The firm has a market cap of $10.24 billion, a PE ratio of 20.97, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.

Insider Buying and Selling

In other news, Director Mary C. Beckerle sold 12,210 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the sale, the director now owns 33,514 shares of the company's stock, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 141,851 shares of company stock worth $5,236,046 in the last ninety days. 2.85% of the stock is owned by corporate insiders.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently made changes to their positions in the company. Coppell Advisory Solutions LLC purchased a new position in Exelixis in the fourth quarter worth $25,000. Colonial Trust Co SC boosted its stake in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 765 shares during the last quarter. USA Financial Formulas acquired a new stake in shares of Exelixis during the 4th quarter worth about $32,000. Principal Securities Inc. grew its stake in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares during the period. Finally, Bartlett & CO. Wealth Management LLC acquired a new position in Exelixis in the first quarter valued at $37,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.